Mi SciELO
Servicios personalizadosServicios Personalizados
Revista
Articulo
Español (pdf)
Articulo en XML
Referencias del artículo
Traducción automática
Enviar articulo por emailIndicadores
Citado por SciELO 
Accesos
Links relacionados
Citado por Google 
Similares en
SciELO 
Similares en Google
Compartir
Permalink
Anales del Sistema Sanitario de Navarra
versión impresa ISSN 1137-6627
Resumen
SIERRA LABARTA, C.R.; SANCHEZ ZALABARDO, D. y PABLO CARDENAS, Á. de. Quality of life in patients diagnosed of prostate cancer treated with continuous androgen deprivation therapy vs. intermittent therapy: prospective study through the application of the CAVIPRES questionnaire. Anales Sis San Navarra [online]. 2015, vol.38, n.2, pp.193-201. ISSN 1137-6627. https://dx.doi.org/10.4321/S1137-66272015000200003.
Background: Treatment with intermittent androgen deprivation (IAD) seeks to improve the quality of life of patients with prostate cancer, with the same oncologic results as continuous androgen deprivation (CAD). The aim of this paper is to compare, using the CAVIPRES questionnaire, the quality of life between two groups of patients, one treated with CAD and the other with IAD. Materials and methods: A longitudinal study was performed for 24 months involving 114 patients. After 6 months, patients were randomized to two treatment groups (49 patients in CAD and 51 patients in IAD), controlled at 6, 12 and 18 months from randomisation. The score of the items and the overall score of the CAVIPRES questionnaire between the two groups was compared and their variation over time was studied. Results: Patients with IAD had a better overall score than patients with CAD (p=0.002). Of the 5 blocks of items into which the questionnaire was divided, the IAD group had a better score than CAD in "Psychological aspects" (p=0.009) and "Social and partner support" (p=0.008). At 18 months, IAD improved the overall quality of life of patients relative to the time of randomization (p=0.000), as well as the score for "Sexual Life" (p=0.000) and "Social and partner support" (p=0.002). CAD did not improve overall quality of life or the score for the different blocks throughout the study (p>0.05). Conclusions: IAD improves overall quality of life of patients at 18 months of stopping treatment.
Palabras clave : Quality of life; Prostate cancer; Intermittent androgen deprivation.
